Hanfstein, B
Shlyakhto, V
Lauseker, M
Hehlmann, R
Saussele, S
Dietz, C
Erben, P
Fabarius, A
Proetel, U
Schnittger, S
Krause, S W
Schubert, J
Einsele, H
Hänel, M
Dengler, J
Falge, C
Kanz, L
Neubauer, A
Kneba, M
Stegelmann, F
Pfreundschuh, M
Waller, C F
Spiekermann, K
Baerlocher, G M
Pfirrmann, M
Hasford, J
Hofmann, W-K
Hochhaus, A
Müller, M C
,
Article History
Received: 6 March 2014
Revised: 30 March 2014
Accepted: 21 April 2014
First Online: 6 May 2014
Competing interests
: The CML-Study IV is supported by the Deutsche Krebshilfe (Nr. 106642), Novartis, Nürnberg, Germany, Kompetenznetz für Akute and Chronische Leukämien (BMBF 01GI0270), José-Carreras Leukämiestiftung (DJCLS H09/01f, H06/04v, H03/01) and the European LeukemiaNet (LSHC-CT-2004-503216). SS declares employment and equity ownership. The remaining authors declare no conflict of interest.